Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. (Q53925847)

22 May 2018

title

Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. (English)

1 reference

22 May 2018

1 reference

W F Keane

1

1 reference

22 May 2018

S K Swan

series ordinal

2

1 reference

22 May 2018

I Grimes

series ordinal

3

1 reference

22 May 2018

T J Humphries

series ordinal

4

1 reference

22 May 2018

publication date

1 September 1999

1 reference

22 May 2018

The Journal of Clinical Pharmacology

published in

1 reference

22 May 2018

volume

39

1 reference

22 May 2018

issue

9

1 reference

22 May 2018

page(s)

927-933

1 reference

22 May 2018

Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents

cites work

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Costs of Acid-Related Disorders to a Health Maintenance Organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Medical Therapy of GERD: current state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

current practice and future perspectives in the management of gastro‐oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Omeprazole is more effective than cimetidine for the relief of all grades of gastro‐oesophageal reflux disease‐associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation*

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Clinical Pharmacokinetics of Lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

A Prospective Randomized Comparative Trial Showing That Omeprazole Prevents Rebleeding in Patients With Bleeding Peptic Ulcer After Successful Endoscopic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Gastric Acid Secretion in Chronic Renal Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Peptic ulceration in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Lansoprazole pharmacokinetics in subjects with various degrees of kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Pharmacokinetics of lansoprazole in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Pharmacokinetics of [14C]omeprazole in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro‐oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/00912709922008542

10.1177/00912709922008542

21 January 2018

Identifiers

DOI

1 reference

22 May 2018

release_3o5r55safzb6npnvjumb7z5pmm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3o5r55safzb6npnvjumb7z5pmm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

22 May 2018